{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:42:02Z","timestamp":1793479322500,"version":"4.5.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Amyloid-targeting therapies (ATTs), including donanemab and lecanemab, are FDA-approved disease-modifying therapies for Alzheimer\u2019s disease in the mild cognitive impairment or mild dementia stages. Early initiation is important for optimal outcomes. This article summarizes practical strategies for implementing ATTs in clinical practice, focusing on leadership alignment and infrastructure development, as well as patient identification, diagnosis, and monitoring protocols. Key recommendations include establishing appropriate patient tracking systems, infusion and imaging protocols, and interprofessional collaboration. Approaches for systematic patient routing (e.g., hub-and-spoke models, fast-track mechanisms) and biomarker-integrated assessments are critical to facilitating timely diagnosis and treatment. Education for patients, care partners, and clinicians is crucial for managing the risks associated with amyloid-related imaging abnormalities. Successful ATT implementation requires coordinated systems, timely diagnosis, and robust safety monitoring. These measures can enable frameworks for ATT administration to optimize outcomes for patients, care partners, and health systems.<\/jats:p>","DOI":"10.3389\/fneur.2026.1863897","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:25:05Z","timestamp":1786433105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Considerations for using amyloid-targeting therapies for the treatment of early symptomatic Alzheimer\u2019s disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Andrew E.","family":"Budson","sequence":"first","affiliation":[{"name":"Neurology Service, Veterans Affairs Boston Healthcare System","place":["Boston, MA, United States"]},{"name":"Alzheimer\u2019s Disease Research Center, Boston University Chobanian and Avedisian School of Medicine","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Ljubenkov","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memory and Aging Center, University of California San Francisco","place":["San Francisco, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ritter","sequence":"additional","affiliation":[{"name":"Hoag Medical Group","place":["Irvine, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Leahy","sequence":"additional","affiliation":[{"name":"Memorial Healthcare","place":["Owosso, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Ramanan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic","place":["Rochester, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Brosch","sequence":"additional","affiliation":[{"name":"Department of Neurology, Indiana University","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Burke","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute","place":["Phoenix, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy R.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"100446","DOI":"10.1016\/j.tjpad.2025.100446","article-title":"Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension","volume":"13","author":"Zimmer","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimer's Res Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","article-title":"Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology","volume":"101","author":"Ramanan","year":"2023","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2025.09.019","article-title":"Establishing an Alzheimer disease therapeutics clinic: experience from a year of evaluations","author":"Neth","year":"2026","journal-title":"Mayo Clin Proc"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1002\/alz.13700","article-title":"How donanemab data address the coverage with evidence development questions","volume":"20","author":"Klein","year":"2024","journal-title":"Alzheimers Dement"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"qxae088","DOI":"10.1093\/haschl\/qxae088","article-title":"Geographic variation in shortfalls of dementia specialists in the United States","volume":"2","author":"Liu","year":"2024","journal-title":"Health Aff Sch"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e70235","DOI":"10.1002\/alz.70235","article-title":"2025 Alzheimer\u2019s disease facts and figures","volume":"21","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref11","year":"2026"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e70102","DOI":"10.1002\/trc2.70102","article-title":"Therapeutic time window of disease-modifying therapy for early Alzheimer's disease","volume":"11","author":"Nakashima","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40120-021-00273-0","article-title":"Predicted lifetime health outcomes for Aducanumab in patients with early Alzheimer\u2019s disease","volume":"10","author":"Herring","year":"2021","journal-title":"Neurol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-024-01399-7","article-title":"Relationships of change in clinical dementia rating (CDR) on patient outcomes and probability of progression: observational analysis","volume":"16","author":"Tariot","year":"2024","journal-title":"Alzheimer's Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12875-025-02977-w","article-title":"An innovative health systems approach to support early detection of cognitive impairment in primary care - the brain health navigator","volume":"26","author":"Brosch","year":"2025","journal-title":"BMC Prim Care"},{"key":"ref16","volume-title":"Kisunla (donanemab) [Package Insert]","year":"2025"},{"key":"ref17","volume-title":"Leqembi (lecanemab) [Package Insert]","year":"2025"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.tjpad.2025.100150","article-title":"Donanemab: Appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e2355800","DOI":"10.1001\/jamanetworkopen.2023.55800","article-title":"Artificial intelligence assistive software tool for automated detection and quantification of amyloid-related imaging abnormalities","volume":"7","author":"Sima","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.3174\/ajnr.A7586","article-title":"Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice","volume":"43","author":"Cogswell","year":"2022","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e70535","DOI":"10.1002\/alz.70535","article-title":"Alzheimer's Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings","volume":"21","author":"Palmqvist","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e14338","DOI":"10.1002\/alz.14338","article-title":"Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","volume":"21","author":"Rabinovici","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e14539","DOI":"10.1002\/alz.14539","article-title":"Usage patterns of cognitive assessments during Medicare's annual wellness visit: a national survey","volume":"21","author":"Liu","year":"2025","journal-title":"Alzheimers Dement"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e2437247","DOI":"10.1001\/jamanetworkopen.2024.37247","article-title":"Annual wellness visits and early dementia diagnosis among Medicare beneficiaries","volume":"7","author":"Tzeng","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"rs.3.rs-5046441","DOI":"10.21203\/rs.3.rs-5046441\/v2","article-title":"Automated medical records review for mild cognitive impairment and dementia","author":"Wei","year":"2024","journal-title":"Res Sq"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s43856-025-01206-w","article-title":"Early prediction of Alzheimer's disease using longitudinal electronic health records of US military veterans","volume":"6","author":"Li","year":"2026","journal-title":"Commun Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1863897\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T07:25:07Z","timestamp":1786433107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1863897\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":29,"alternative-id":["10.3389\/fneur.2026.1863897"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1863897","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1863897"}}